European Regulators Back Expanded Use of Amgen's Repatha for Heart Disease Prevention

The EMA's CHMP has issued a positive opinion for Amgen's Repatha, recommending its broader use for adults with established or high risk of atherosclerotic cardiovascular disease. This expansion aims to reduce cardiovascular events by lowering LDL-C, based on Phase 3 VESALIUS-CV trial results, offering a new preventative option for high-risk patients.